TickerGuard
Buy Day today: Poor (42) Weak market breadth · today: Nonfarm Payrolls (October)
TELO

Telomir Pharmaceuticals, Inc.

Healthcare · Biotechnology

0.7801$ -10.8% vs. previous close Closing price · As of: Nov 5, 2026

Ownership

Ownership Structure

Who owns Telomir Pharmaceuticals, Inc. (TELO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 53.3% of the shares are freely tradable; institutional investors hold 3.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 3.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 35.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 53.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 1.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 74Mio.

Largest Shareholders

Institutions

Institutions TELO
Name Stake (%) Shares Change (%) Date
Vanguard Capital Management, LLC 4.69 1,613,639 +62.1 06/30/2026
Geode Capital Management, LLC 0.99 338,875 +36.0 06/30/2026
BlackRock Inc 0.82 280,472 -3.0 06/30/2026
Vanguard Fiduciary Trust Co 0.66 225,304 +66.2 06/30/2026
Northern Trust Corp 0.18 61,532 +47.1 06/30/2026
State Street Corp 0.17 58,600 +0.0 06/30/2026
Bank of New York Mellon Corp 0.15 51,454 +0.0 06/30/2026

Funds

Funds TELO
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 3.26 1,121,175 +0.0 09/30/2026
Fidelity Extended Market Index 0.61 209,276 -0.5 08/31/2026
iShares Micro-Cap ETF 0.33 113,747 -0.7 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?